PPT-Switching to TAF from TDF, each with RPV and FTC

Study GS3661216 Switch from TDF to TAF each with RPV and FTC Study GS3661216 Design Source Orkin C et al Lancet HIV 20174e195e204 NOTE of 632 participants randomized 2 were never treated 630 individuals treated. PROBE . Study. PROBE Study: switch to DRV/r + RPV . Design. Age ≥ 18 years. HIV+. No previous resistance to study drugs. HIV-1 RNA. < 50 c/ml ≥ 6 months. On stable (≥ 6 months) . PI/r + 2 NRTI (TDF/FTC or ABC/3TC). STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Estudio GS-US-311-1089 . Estudio GS-US-366-1216 . Estudio GS-US-366-1160 . . Diseño. Endpoints. Primario: proporción de pacientes . con C. V . < 50 c/mL a S48 (ITT, . snapshot. ) ; no inferioridad si el margen inferior de IC95% de dos colas para la diferencia = - 8%, poder 85%. Treating and Preventing HIV in 2019: Interactive Cases From the Clinic(ians) Michael S. Saag , MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials Andrew Hill, Francois Venter, Eric Delaporte , Simiso Sokhela, Charles GS-US-292-0109 Study. GS-US-311-1089 Study. . Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (ITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -10%, > 95% power. Kiat. . Ruxrungtham. Professor of Medicine, . Chulalongkorn University; and. HIV-NAT, Thai Red Cross AIDS Research Center. Three Decades of HIV/AIDS . Learning and the Future. Mid 1990. 1981. 2012 - 2014. Heathland ingWoodland ingRoom ypeSundewHazelOrchidBirchGorseHollyBrackenAshHeatherOakMossBeech4/5 Bedded Pupil RoomSundewOrchidEXITSOUTHGorseBrackenHeatherMossEntranceLibraryAshHollyBirchHazelOakBeech in a Single-Tablet Regimen . in Initial HIV-1 Therapy. Combined Primary Results of . Studies GS-US-292-0104 and GS-US-292-0111. David Wohl. 1. , Anton Pozniak. 2. , Melanie Thompson. 3. , Edwin DeJesus. and . Virologic. Outcomes . for Treatment-experienced . People Living with HIV Switching to MTR or STR ART since 2018 . Ben Chastek. 1. , Amy Anderson. 1. , Joshua Gruber. 2. , Sunil Majethia. 2. , Woodie Zachry. ADVANCE. . Design. Primary endpoint. Proportion of patients with HIV RNA < 50 c/mL at W48, ITT-E snapshot analysis ; non-inferiority of TFA/FTC if lower margin CI for . the difference = - 10%, 80% power. With Emergence of Comorbidities. Roger J. . Bedimo. , MD. Professor of Medicine. University of Texas Southwestern Medical Center. Dallas, TX. Learning Objectives. On completion of this presentation, learners will be able to:. SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed . Associate Dean for Global Health. University of Alabama at Birmingham. Birmingham, Alabama. Cases from the Clinic(. ians. ): . Case. -based Panel Discussion. AU Final: 02/21/17. New York, New York: February 24, 2017.